Sai Parenterals Ltd
Sai Parenterals Ltd (SAIPARENT) last reported results for the quarter ended Jun 2026, with sales of ₹179 crore and net profit of ₹7.92 crore. Sai Parenterals Ltd’s board meets on 14 Oct 2026. The stock last traded at ₹509, a market capitalisation of ₹2,248 crore, on a P/E of 108. Over the past 52 weeks the stock has ranged between ₹400 and ₹706. Figures are as of 6 Oct 2026 and are not real time.
Sai Parenterals Ltd share price and key metrics
- Current price
- ₹509
- Market cap
- ₹2,248 cr
- Stock P/E
- 108
- ROE
- 4.88%
- ROCE
- 5.28%
- Dividend yield
- 0.00%
- 52w high / low
- 706/400
Metrics as of 6 Oct 2026. Not real time.
Track Sai Parenterals Ltd
Cruxal reads every Sai Parenterals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sai Parenterals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 58%
- TTM
- 134%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 48%
- TTM
- -1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 9%
- Last Year
- 5%
Sai Parenterals Ltd quarterly results
| ₹ crore | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 33.39 | 96.15 | 198 | 179 |
| Expenses | 28.65 | 99.71 | 172 | 155 |
| Operating profit | 4.74 | -3.56 | 26.1 | 23.52 |
| OPM % | 14.20% | -3.70% | 13.19% | 13.16% |
| Other income | 1.17 | 3.13 | 2.88 | 3.74 |
| Interest | 2.46 | 5.41 | 8.4 | 9.36 |
| Depreciation | 1.45 | 5.79 | 8.18 | 8.11 |
| Profit before tax | 2 | -11.63 | 12.4 | 9.79 |
| Tax % | 29.50% | -42.65% | -6.13% | 19.00% |
| Net profit | 1.42 | -6.66 | 13.16 | 7.92 |
| EPS (₹) | 0.52 | -1.80 | 2.98 | 1.79 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sai Parenterals Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 97 | 154 | 163 | 381 |
| Operating profit | 19 | 32 | 39 | 39 |
| OPM % | 19% | 21% | 24% | 10% |
| Net profit | 4 | 8 | 14 | 14 |
| EPS (₹) | 6.13 | 6.36 | 5.43 | 3.23 |
TTM is the trailing twelve months to the most recent quarter.
Sai Parenterals Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings | 69 | 119 | 94 | 469 |
| Other liabilities | 34 | 75 | 85 | 465 |
| Total liabilities | 134 | 268 | 272 | 1,424 |
| Fixed assets | 44 | 70 | 53 | 364 |
| CWIP | 2 | -0 | 0 | 212 |
| Investments | -0 | -0 | -0 | -0 |
| Other assets | 88 | 198 | 219 | 848 |
| Total assets | 134 | 268 | 272 | 1,424 |
As reported by the company. Total assets equal total liabilities by construction.
Sai Parenterals Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | -13 | -30 | 33 | 93 |
| Cash from investing | -19 | -46 | 0 | -274 |
| Cash from financing | 24 | 79 | -36 | 596 |
| Net cash flow | -8 | 2 | -2 | 415 |
| Free cash flow | -30 | -72 | 41 | -184 |
| CFO / operating profit | -54% | -94% | 86% | 253% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sai Parenterals Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | 16% | 17% | 5% |
| Debtor days | 231 | 302 | 283 | 173 |
| Inventory days | 83 | 143 | 199 | 259 |
| Days payable | 140 | 203 | 225 | 224 |
| Cash conversion cycle | 174 | 242 | 256 | 208 |
| Working capital days | 19 | 72 | 79 | -161 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sai Parenterals Ltd shareholding pattern
Promoters held 51.16% at Jun 2026, broadly unchanged since Mar 2026. FIIs 4.03% and DIIs 8.52%.
| % held | Mar 2026 | Jun 2026 |
|---|---|---|
| Promoters | 51.16% | 51.16% |
| FIIs | 5.73% | 4.03% |
| DIIs | 12.86% | 8.52% |
| Public | 30.25% | 36.29% |
| No. of shareholders | 7,687 | 9,312 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When does Sai Parenterals Ltd’s board next meet?
Sai Parenterals Ltd’s board meets on 14 Oct 2026.
- Board meetingInvestor/Analyst meeting to discuss disclosures under Regulation 30
See the full results calendar for every Indian company reporting in the next 30 days.
Sai Parenterals Ltd corporate filings
- RTA''s CertificateCompany Updatelow impact
- Sai Parenterals Limited completes strategic acquisition of 60% stake in Prathyak Laboratories for Rs. 15 crore, establishing an operational R&D platform in HyderabadCompany Updatehigh impact
Cruxal's analysis: Sai Parenterals Limited has acquired a 60% equity stake in Prathyak Laboratories for Rs…
Read the full analysis - Monitoring agency report for Sai Parenterals Ltd for quarter ended 30 June 2026 releasedCompany Updatelow impact
Cruxal's analysis: The company has issued a monitoring agency report for Q1 FY2026, covering the period…
Read the full analysis - Sai Parenterals schedules analyst and institutional investor meetings under Regulation 30 for October 2026Company Updatelow impact
Cruxal's analysis: The company has announced meetings with analysts and institutional investors scheduled…
Read the full analysis - for the declaration of unaudited financial results for the quarter and half year ended 30th September, 2026Insider Trading / SASTlow impact
- Sai Parenteral’s Limited Board approves leadership changes including resignation of CS & appointment of COO, with no immediate financial impact disclosedOtherslow impact
Cruxal's analysis: Sai Parenteral’s Limited announced the resignation of its Company Secretary & Compliance…
Read the full analysis - Sai Parenterals Limited Announces Successful Conclusion of AGM and Approval of Key Strategic ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Sai Parenterals Limited has successfully concluded its Annual General Meeting held on…
Read the full analysis - Sai Parenterals Limited concludes 25th AGM; shareholders approve key resolutions including IPO proceeds utilization and related party transactionsAGM/EGMmedium impact
Cruxal's analysis: Sai Parenterals Limited has successfully concluded its 25th Annual General Meeting, where…
Read the full analysis - Sai Parenterals Ltd files routine Regulation 30 disclosureCompany Updatelow impact
Cruxal's analysis: Sai Parenterals Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Sai Parenterals Limited secures 204 crore OTC supply contract renewal with Australian pharmacy chainCompany Updatehigh impact
Cruxal's analysis: Sai Parenterals Limited has announced that its subsidiary, Noumed Pharmaceuticals Pty…
Read the full analysis - Sai Parenterals Ltd schedules analyst and institutional investor meeting for August 31, 2026Company Updatelow impact
Cruxal's analysis: Sai Parenterals Ltd has announced a scheduled meeting with analysts and institutional…
Read the full analysis - Sai Parenterals Ltd announces newspaper publication for 25th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Sai Parenterals Ltd has published a notice in newspapers regarding its 25th Annual…
Read the full analysis - Sai Parenterals Ltd publishes Form PAS-1 regarding variation in utilization of IPO proceedsCompany Updatelow impact
Cruxal's analysis: The company has submitted a newspaper publication in Form PAS-1, formally notifying…
Read the full analysis - Sai Parenterals Limited announces Book Closure and Cut-Off Date for 25th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Sai Parenterals Limited has formally notified the exchanges regarding the closure of its…
Read the full analysis - Sai Parenterals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Sai Parenterals Ltd has filed its Annual Report for the financial year 2025-26 as per…
Read the full analysis - Sai Parenterals Limited Announces 25th AGM and Proposes Strategic Reallocation of IPO ProceedsAGM/EGMhigh impact
Cruxal's analysis: Sai Parenterals Limited has scheduled its 25th Annual General Meeting for September 10…
Read the full analysis - Sai Parenterals Q1 FY27 Earnings Call: Strategic Pivot in IPO Fund Utilization and Expansion into Critical Care InjectablesCompany Updatehigh impact
Cruxal's analysis: Sai Parenterals Limited reported Q1 FY27 consolidated revenue of 182 crore and PAT of 8…
Read the full analysis - Sai Parenterals Limited releases audio recording of Q1 FY2027 earnings conference callCompany Updatelow impact
Cruxal's analysis: Sai Parenterals Limited has formally disclosed the audio recording of its post-earnings…
Read the full analysis - Sai Parenterals Limited Announces Strategic Reallocation of IPO Proceeds for Acquisitions in Injectable and R&D CapabilitiesCompany Updatehigh impact
Cruxal's analysis: Sai Parenterals Limited has announced a strategic variation in the utilization of its IPO…
Read the full analysis - Sai Parenterals Ltd files routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Sai Parenterals Ltd has submitted a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.